Novel Hybrid Series of Compound Derived from 2-Aminotetralin and Piperazine Based Derivatives: Characterization for D1, D2, D3, D4 and other Serotonin Receptor Subtypes Binding

Case ID:
00-497

A series of compounds derived from 2-aminotetralin and piperazine fragments have been synthesized, which exhibit high CNS activity in vivo and in vitro. Some of the selected lead compounds have exhibited potent in vivo activity in a Parkinson?s disease animal model with long extended duration of action. In particular, these compounds show high D3 receptor affinity and/or high D3/D2 selectivity. In addition to the potential therapeutic treatment of Parkinson?s disease and depression, these novel compounds have possible application in the treatment of a number of other neurological disorders such as cocaine addiction, restless leg syndrome or as an atypical antipsychotic agent.

Commercial Applications

·         Atypical Antipsychotics

·         Medication for Neurodegenerative Diseases

·         Anti-depressants

·         Treatment of Addiction

Patent Status

U.S. patent 6,982,332 is available for an exclusive license.

Tech ID

00-497

 

Patent Information:
For Information, Contact:
Joan Dunbar
Associate Vice President for Technology Commercialization
Wayne State University
(313) 577-5542
jcdunbar@med.wayne.edu
Inventors:
Aloke Dutta
Xiang-Shu Fei
Keywords: